Creso Pharma (ASX:CPH) share price sinks 9% on update

The Creso Pharma Ltd (ASX:CPH) share price is sinking on Friday after releasing an announcement. Here’s what you need to know…
The post Creso Pharma (ASX:CPH) share price sinks 9% on update appeared first on The Motley Fool Australia. –

Thumbs down Facebook icon over dark screen

It has been a volatile morning for the Creso Pharma Ltd (ASX: CPH) share price after returning from a trading halt.

After being up as much as 5.5% to 19 cents, the cannabis and psychedelics company’s shares are now down 9% to 16.3 cents.

Why was the Creso Pharma share price in a trading halt?

Creso Pharma requested a trading halt on Wednesday pending the release of a “material operational update” in relation to its proposed acquisition target, Halucenex Life Sciences.

This morning the company revealed that the material development that required a two-day trading halt was that Halucenex Life Sciences has secured an additional 10 grams of synthetic psilocybin from its manufacturing partner. Combined with its existing inventory, Halucenex Life Sciences now has total pharmaceutical grade psilocybin of 22.3 grams.

As small as this sounds, this still makes it one of the largest holders of single batch GMP grade synthetic psilocybin in Canada. According to the release, the psilocybin will be used in research and development initiatives and future clinical trials.

Management commentary

Judging by the weakness in the Creso Pharma share price, investors appear underwhelmed by this announcement.

Nevertheless, Creso Pharma’s Non-Executive Chairman, Adam Blumenthal, believes it is an important development.

He commented: “Halucenex is now one of the largest holders of single batch GMP grade synthetic psilocybin in Canada. This is a major development and opens a number of doors for Halucenex in medium and long term.”

“Once it secures its licence from Health Canada, Halucenex will have the capacity to progress a number of R&D initiatives, which have the potential to unlock new drug delivery methods and combinations, potentially leading to a higher level of care through alternative treatment methods. We look forward to working with Halucenex and its existing partners to progress these research initiatives.”

“Halucenex and the Creso group more broadly continues to make steps forward. We have achieved a number of regulatory hurdles in regards to the proposed US OTC listing and anticipate DTC eligibility shortly. This will unlock considerable benefit for shareholders. We are very excited to share some of the developments the Company has been working on in the coming months,” he concluded.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Creso Pharma (ASX:CPH) share price sinks 9% on update appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!